Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PT Prodia Widyahusada TbkISX:PRDA +1.69%72 EV-to-EBITDA is 2.90 as of Aug. 01, 2026, which is 55% below its 10-year median of 6.42. GuruFocus rates ISX:PRDA with a GF Score™ of 72/100 and a GF Value™ of Rp3,140.38 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 119 Medical Diagnostics & Research companies, PT Prodia Widyahusada Tbk ranks better than 92.44% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, PT Prodia Widyahusada Tbk's enterprise value is Rp1,382,716 Mil.
PT Prodia Widyahusada Tbk's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was Rp477,388 Mil. Therefore, PT Prodia Widyahusada Tbk's EV-to-EBITDA for today is 2.90.
The historical rank and industry rank for PT Prodia Widyahusada Tbk's EV-to-EBITDA or its related term are showing as below:
ISX:PRDA'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 2.78 Med: 6.42 Max: 81.6
Current: 2.89
During the past 13 years, the highest EV-to-EBITDA of PT Prodia Widyahusada Tbk was 81.60. The lowest was 2.78. And the median was 6.42.
ISX:PRDA's EV-to-EBITDA is ranked better than 92.44% of 119
companies
in the Medical Diagnostics & Research industry
Industry Median: 15.76
vs ISX:PRDA: 2.89
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
PT Prodia Widyahusada Tbk's PE Ratio (TTM) for today is calculated as:
PT Prodia Widyahusada Tbk's share price for today is Rp2400.00.
PT Prodia Widyahusada Tbk's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was Rp237.646.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ISX:PRDA vs TMO, DHR, IDXX: EV-to-EBITDA Comparison
For the Diagnostics & Research subindustry, PT Prodia Widyahusada Tbk's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PT Prodia Widyahusada Tbk EV-to-EBITDA vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, PT Prodia Widyahusada Tbk's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where PT Prodia Widyahusada Tbk's EV-to-EBITDA falls into.
PT Prodia Widyahusada Tbk's current Enterprise Value is Rp1,382,716 Mil.
PT Prodia Widyahusada Tbk's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was Rp477,388 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PT Prodia Widyahusada Tbk (ISX:PRDA) has a EV-to-EBITDA of 2.90 as of Aug. 01, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on PT Prodia Widyahusada Tbk. This is 55% below median its historical median of 6.42. Over the past decade, PT Prodia Widyahusada Tbk's EV-to-EBITDA has ranged from 2.78 to 81.60. According to the industry distribution chart, PT Prodia Widyahusada Tbk ranks #9 out of 119 companies in the Medical Diagnostics & Research industry, placing it in the top 7.6%.
Is PT Prodia Widyahusada Tbk's EV-to-EBITDA too high?
PT Prodia Widyahusada Tbk's current EV-to-EBITDA of 2.90 is 55% below median its 10-year median of 6.42. Over the past 10 years, this metric has ranged from a low of 2.78 to a high of 81.60. The Medical Diagnostics & Research industry median EV-to-EBITDA is 15.76. PT Prodia Widyahusada Tbk's value of 2.90 is 81.6% below this industry median. Based on the distribution chart, PT Prodia Widyahusada Tbk ranks #9 out of 119 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, PT Prodia Widyahusada Tbk has a GF Score™ of 72/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does PT Prodia Widyahusada Tbk's EV-to-EBITDA compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, PT Prodia Widyahusada Tbk ranks #9 out of 119 companies for EV-to-EBITDA. This places PT Prodia Widyahusada Tbk in the top 8% of its industry — outperforming the majority of peers. The industry median EV-to-EBITDA is 15.76. PT Prodia Widyahusada Tbk's value of 2.90 is 81.6% below this benchmark. Historically, PT Prodia Widyahusada Tbk's own EV-to-EBITDA has ranged from 2.78 to 81.60 over the past decade. While the company's 10-year median is 6.42 vs. the industry median of 15.76, PT Prodia Widyahusada Tbk has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Diagnostics & Research company?
The median EV-to-EBITDA among Medical Diagnostics & Research companies is 15.76, based on 119 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PT Prodia Widyahusada Tbk's current EV-to-EBITDA of 2.90 is 81.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on PT Prodia Widyahusada Tbk. For the Medical Diagnostics & Research industry, the median EV-to-EBITDA is 15.76 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PT Prodia Widyahusada Tbk's current EV-to-EBITDA is 2.90, which is 55% below median its own 10-year median of 6.42. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PT Prodia Widyahusada Tbk stock overvalued right now?
Based on GuruFocus' analysis, PT Prodia Widyahusada Tbk (ISX:PRDA) is currently considered Modestly Undervalued. The stock's GF Value™ is Rp3,140.38, compared to a current price of Rp2,400.00 — trading 23.6% below its estimated fair value. The current EV-to-EBITDA is 2.90, which is 55% below median its 10-year median of 6.42 and 81.6% below the Medical Diagnostics & Research industry median of 15.76. PT Prodia Widyahusada Tbk's overall GF Score™ is 72/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For PT Prodia Widyahusada Tbk (ISX:PRDA), the current EV-to-EBITDA is 2.90 as of Aug. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PT Prodia Widyahusada Tbk (ISX:PRDA) Overvalued in 2026?
Based on GuruFocus' analysis, PT Prodia Widyahusada Tbk stock appears to be undervalued.
The current stock price of Rp2,400.00 is trading 23.6% below its estimated GF Value™ of Rp3,140.38.
GuruFocus considers PT Prodia Widyahusada Tbk to be Modestly Undervalued.
Key valuation signals for ISX:PRDA:
EV-to-EBITDA: 2.90 (55% below median its 10-year median of 6.42)
GF Value™: Rp3,140.38 vs. price of Rp2,400.00 (23.6% below fair value)
Industry Position: 81.6% below the Medical Diagnostics & Research median (#9 of 119)
No single metric tells the full story. See the ISX:PRDA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PT Prodia Widyahusada Tbk provides health care testing services. The company provides analytic and diagnostic services for the medical professionals. It is engaged in health laboratories by conducting business activities such as setting up clinics, health laboratories, management of hospitals, and health checkup services. Its operating segments are Central: Jakarta; Sumatera: Sumatera, Kepulauan Riau; Greater Jakarta: Jakarta, Bogor, Depok, Tangerang, Bekasi, Lampung, Pangkal Pinang; West Java; Central Java; East Java, Bali, Nusa Tenggara; Kalimantan Sulampua: Kalimantan, Sulawesi, Ambon, Papua.
72GF Score
Get the complete analysis for ISX:PRDA
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ISX:PRDA has been successfully added to your 
